Physician profile
Michael L Brenner
NPI 1114992674
$17,140.10
in general payments reported to CMS, 2019-2025
61 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $1,265 · 2021: $1,791 · 2022: $1,665 · 2023: $2,063 · 2024: $6,418 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,418 · Education: $69.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,492.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,417.50 |
| Education | $69.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $4,619.93 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $1,648.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,168.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,155.77 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,097.52 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $1,069.42 | 2019-2025 | |
| Lilly USA, LLC | $879.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $750.78 | 2019-2025 | Bexsero, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.53 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $509.16 | 2021-2025 | |
| Astellas Pharma US INC | $347.47 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $257.32 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Aimmune Therapeutics, INC. | $255.66 | 2024 | |
| Radius Health, INC. | $253.48 | 2019-2025 | Tymlos |
| Esperion Therapeutics, INC. | $246.58 | 2020-2025 | Nexletol |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.